Caplin Point Laboratories

1,994.40
-15.70
(-0.78%)
Market Cap
15,159.77 Cr
EPS
60.19
PE Ratio
29.59
Dividend Yield
0.25 %
Industry
Healthcare
52 Week High
2,641.00
52 Week Low
1,225.00
PB Ratio
6.00
Debt to Equity
0.00
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from2 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy+100.00 %
+100.00 %
Hold0.0 %
0.0 %
Sell0.0 %
0.0 %
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
1,725.35
#1 4,13,969.26
35.22
#1 49,887.20
12.06
#1 9,648
13.77
54.16
5,773.30
1,53,262.98
75.20
8,184.00
0.89
1,600
#1 64.53
56.90
1,446.00
1,16,781.12
24.00
26,520.70
14.17
4,155
47.38
51.80
3,215.15
1,08,815.29
58.64
10,785.70
11.59
1,656
13.54
59.74
2,421.15
99,891.45
49.78
10,615.60
19.57
1,942
-16.38
59.91
1,146.35
95,657.79
#1 18.06
28,905.40
12.36
5,578
1.69
47.74
2,006.10
91,586.68
32.14
20,141.50
#1 19.94
1,936
38.82
47.45
884.60
89,011.46
19.77
19,831.50
13.82
3,831
29.92
42.86
1,153.40
66,989.66
19.21
29,559.20
17.55
3,169
-10.04
53.81
30,728.60
65,296.13
48.70
6,097.20
10.80
1,201
16.01
55.29
Growth Rate
Revenue Growth
15.65 %
Net Income Growth
22.39 %
Cash Flow Change
17.33 %
ROE
-0.56 %
ROCE
1.57 %
EBITDA Margin (Avg.)
7.57 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
64
71
78
81
84
87
98
105
122
127
135
144
146
148
163
167
190
197
234
239
235
247
270
280
288
310
312
336
351
360
376
386
401
407
431
453
471
478
504
524
Expenses
48
51
57
57
61
63
68
71
75
78
82
91
95
93
100
101
123
125
156
160
161
169
181
191
193
208
202
225
239
244
254
263
265
269
273
293
308
307
318
331
EBITDA
16
20
22
24
22
24
30
34
48
50
53
53
52
55
63
66
67
72
78
78
73
78
89
90
95
102
110
111
111
116
122
124
135
139
158
160
163
170
185
194
Operating Profit %
24 %
27 %
27 %
29 %
25 %
26 %
29 %
31 %
37 %
37 %
38 %
36 %
34 %
36 %
36 %
36 %
35 %
35 %
31 %
30 %
25 %
30 %
33 %
31 %
31 %
31 %
33 %
31 %
29 %
30 %
29 %
29 %
32 %
32 %
34 %
33 %
32 %
33 %
34 %
33 %
Depreciation
1
3
2
3
3
3
3
3
5
4
4
5
6
5
6
6
7
7
7
8
8
9
9
9
10
12
12
12
11
11
12
11
11
11
12
14
16
16
17
16
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Profit Before Tax
15
16
20
21
20
21
27
31
43
46
49
49
45
49
57
60
61
64
71
70
65
69
80
80
85
90
98
99
100
105
110
112
124
127
146
145
146
154
169
177
Tax
4
4
5
5
4
5
5
7
9
10
13
11
10
12
14
14
11
14
13
11
16
14
17
14
17
18
21
19
19
19
18
14
23
23
30
26
25
30
38
37
Net Profit
11
13
14
16
16
16
22
24
33
36
36
38
35
37
44
46
50
50
57
59
49
55
63
66
68
72
77
79
81
86
92
97
101
104
116
120
121
125
131
140
EPS in ₹
7.02
8.40
1.86
10.66
10.31
10.55
14.85
3.15
4.41
4.81
4.71
4.97
4.76
4.95
6.21
6.06
6.58
6.64
7.58
7.74
6.46
7.21
7.52
8.52
8.78
9.37
9.91
9.90
10.43
11.21
12.09
12.86
13.45
13.62
15.13
15.44
16.01
16.32
17.22
18.28

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
229
267
358
501
743
1,126
1,364
1,736
2,191
2,698
Fixed Assets
113
144
152
170
227
273
305
287
280
453
Current Assets
82
119
179
304
494
823
1,015
1,298
1,552
1,893
Capital Work in Progress
31
0
3
15
10
20
14
18
221
117
Investments
0
0
17
47
70
61
11
89
281
376
Other Assets
85
123
186
269
436
772
1,033
1,343
1,410
1,753
Total Liabilities
229
267
358
501
743
1,126
1,364
1,736
2,191
2,698
Current Liabilities
125
125
113
109
86
144
143
208
268
331
Non Current Liabilities
10
14
20
28
23
25
17
19
16
20
Total Equity
94
128
225
364
633
957
1,203
1,510
1,907
2,347
Reserve & Surplus
78
113
210
349
514
716
954
1,252
1,649
2,084
Share Capital
15
15
15
15
15
15
15
15
15
15

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
19
23
25
-14
74
70
215
-81
27
-39
Investing Activities
-23
-6
-36
-69
-100
-54
-30
-377
-216
-319
Operating Activities
50
42
68
67
83
45
269
337
271
318
Financing Activities
-9
-14
-7
-12
90
80
-24
-41
-28
-38

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Promoter
69.03 %
69.03 %
69.03 %
68.91 %
68.89 %
68.88 %
68.88 %
68.80 %
70.66 %
70.63 %
70.63 %
70.62 %
70.62 %
70.56 %
70.56 %
70.56 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
3.09 %
2.85 %
3.34 %
3.37 %
3.70 %
4.86 %
DIIs
1.28 %
1.44 %
1.14 %
1.16 %
1.20 %
1.07 %
1.12 %
1.12 %
0.65 %
0.26 %
0.20 %
0.43 %
1.09 %
1.49 %
1.84 %
2.11 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
22.94 %
21.69 %
20.93 %
20.79 %
20.79 %
20.76 %
19.00 %
18.91 %
18.73 %
18.57 %
18.31 %
18.36 %
17.59 %
17.50 %
17.12 %
15.77 %
Others
6.75 %
7.85 %
8.90 %
9.13 %
9.12 %
9.28 %
11.00 %
11.17 %
9.96 %
10.53 %
7.77 %
7.74 %
7.36 %
7.08 %
6.78 %
6.70 %
No of Share Holders
68,076
69,524
83,462
85,577
83,829
84,868
84,538
82,687
82,146
78,956
78,068
79,438
81,409
80,411
96,123
92,702

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 1.5 2 2.2 2.5 3 4 4.5 5 0.00
Dividend Yield (%) 0.00 0.26 0.5 0.78 0.62 0.44 0.68 0.34 0.25 0.00

Corporate Action

Announcements

Closure of Trading Window2 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 26, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 26, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 14, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 08, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 07, 2025
Integrated Filing (Financial)Feb 07, 2025
Board Meeting Outcome for Board Meeting Outcome Of The Financial Results For The Quarter Ended December 31 2024Feb 07, 2025
Financial Results For The Quarter Ended December 31 2024Feb 07, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 05, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 31, 2025
Board Meeting Intimation for Board Meeting Intimation For Considering And Approving Un-Audited Financial ResultsJan 31, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 17, 2025
UpdateJan 06, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 03, 2025
Closure of Trading WindowDec 27, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 16, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateDec 12, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 09, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 15, 2024
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 14, 2024
Announcement under Regulation 30 (LODR)-CessationNov 08, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 08, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 07, 2024
Financials Results For The Quarter And Half-Year Ended September 30, 2024Nov 07, 2024
Board Meeting Outcome for Financial Results For The Quarter And Half-Year Ended September 30, 2024Nov 07, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 30, 2024
Board Meeting Intimation for Intimation Of Board MeetingOct 30, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateOct 23, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 10, 2024
Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportOct 01, 2024
Announcement under Regulation 30 (LODR)-Change in DirectorateSep 30, 2024
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 30, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateSep 30, 2024
Closure of Trading WindowSep 26, 2024
Issuance Of Bonus Equity Shares By Caplin Point Far East Limited - Hong Kong, Wholly Owned Material Subsidiary Of The CompanySep 19, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateSep 16, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 06, 2024
Notice Of 33Rd AGM Of The Company To Be Held On September 30, 2024 Through VC/OAVMSep 06, 2024
Business Responsibility and Sustainability Reporting (BRSR)Sep 06, 2024
Reg. 34 (1) Annual Report.Sep 06, 2024
Reply To Clarification Sought By Exchange For Spurt In Volume In Shares Of The CompanySep 06, 2024
Clarification sought from Caplin Point Laboratories LtdSep 06, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 29, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateAug 24, 2024
Completion Of Inspection By ANVISA - BrazilAug 16, 2024
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 14, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateAug 10, 2024
UpdateAug 09, 2024
Press ReleaseAug 09, 2024

Technical Indicators

RSI(14)
Neutral
53.25
ATR(14)
Volatile
91.78
STOCH(9,6)
Neutral
77.78
STOCH RSI(14)
Neutral
79.24
MACD(12,26)
Bullish
24.73
ADX(14)
Weak Trend
20.92
UO(9)
Bearish
55.31
ROC(12)
Uptrend And Accelerating
5.37
WillR(14)
Neutral
-29.20

About Caplin Point Laboratories

Caplin Point Laboratories Limited is an Indian pharmaceutical company founded in 1990. It develops, produces, and markets generic formulations and branded products globally. The company has manufacturing facilities in India and serves markets in Latin America, Africa, the USA, and the European Union. Caplin Point specializes in various pharmaceutical formulations, including injectables, tablets, capsules, and syrups. The company has expanded through acquisitions, partnerships, and investments in subsidiaries. It has a strong presence in emerging markets and has entered regulated markets like the USA. Caplin Point has invested in research and development, including API development and clinical research. The company has also ventured into e-commerce and has been expanding its product portfolio and manufacturing capabilities.
Chairperson NameC C Paarthipan